SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pupu is a community-driven meme project centered around the character “Pupu the Frog,” who represents lighthearted fun and adventure within the crypto space. The project aims to build a digital ecosystem where holders can engage with the narrative of Pupu through memes, social interactions, and community activities. At its core, the project highlights creativity, entertainment, and community participation as primary utilities, while maintaining a transparent and decentralized structure that evolves through user engagement.

Pupu

PUPU CRYPTO is trending as the community rallies behind it, drawing comparisons to PEPE and DOGE while aiming for a $1 billion market cap. Built on the Solana blockchain, traders are highlighting its accessibility via Phantom Wallet and anticipating a potential breakout. The coin's momentum is being fueled by the broader excitement around meme coins.

VanEck ETF Trust - VanEck Oil Services ETF

VanEck Oil Services ETF

The VanEck Oil Services ETF ($OIH) is trending due to a mix of factors, including geopolitical tensions from Ukrainian attacks on Russian oil infrastructure and OPEC+ production decisions. Community discussions revolve around potential upside in the Oil Services sector, which has been lagging behind broader energy market gains, with some traders anticipating a significant move. Despite concerns over a possible oil supply surplus, some analysts and traders are pointing to robust demand and potential for sector outperformance.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the idea of bringing back OG meme culture in blockchain form. Community members express conviction and encourage each other to 'RAGE HARDER' and 'believe in something'. The broader discussion centers on the return to cults and memes, moving away from fleeting trends.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as the crypto community discusses its recent price surge and potential as a privacy-focused alternative to Bitcoin. Community members are weighing in on potential price targets, the impact of institutional investment from figures like the Winklevoss twins, and its possible role in a shifting crypto landscape. Some traders believe ZEC has strong upside potential due to its privacy features, while others caution against the high volatility.

Newsmax Inc. is a holding company, which engages in television broadcasting and multi-platform content publishing that produces original news and editorial content for consumers through various media outlets, including TV new channels, digital and print publications. It operates through the Broadcasting and Digital Segments. The Broadcasting segment produces and licenses news, business news and lifestyle content for distribution through both MVPDs and free OTT streaming platforms. The Digital segment is composed of Newsmax.com and affiliated websites. The company was founded by Christopher Ruddy in 1998 and is headquartered in Boca Raton, FL.

Newsmax Inc. - Ordinary Shares - Class B

Newsmax Inc

Newsmax ($NMAX) is trending amid discussions around its relationship with political figures and potential market manipulation. Community members are actively debating the stock's valuation, recent earnings report, and its appeal as a potential acquisition target. Some traders are closely monitoring trading patterns, alleging possible short-selling tactics and coordinated efforts to suppress the stock price.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic ($LUNC) is trending as the community discusses its potential for a run, while also grappling with concerns about scams and continuous crashes. The crypto market's overall health, government re-openings, and staking rewards are also hot topics among investors. Community members are closely watching for potential catalysts, including the LUNCVERSE Alpha launch and future exchange re-listings.

What is the project about?   Horizen is a modular privacy-first platform designed to make privacy technology, such as zero-knowledge proofs and TEEs accessible and usable across the web. Originally launched in 2017 as a fair launch, non-ICO project, Horizen is now undergoing a major evolution with the launch of Horizen 2.0, a next-generation Layer 3 (L3) appchain deployed on Base, the Ethereum Layer 2 developed by Coinbase.  Horizen 2.0 is built as an Ethereum-aligned Layer 3 appchain on Base, inheriting Ethereum's security while implementing its own application-level integrity guarantees.    Key components of Horizen’s security model include:  Ethereum-Aligned Security: As an appchain deployed on Base, Horizen 2.0 benefits from Base’s rollup security and settlement on Ethereum, ensuring robust finality and composability with other L2 and L3 applications.  Simplified and Secure Architecture: Unlike Horizen’s previous iterations (which used a hybrid PoW/PoS model), Horizen 2.0 focuses on application-level security, decentralization of its privacy layers, and composability with existing infrastructure — reducing complexity and increasing user safety.  Decentralized Privacy Stack: Horizen’s focus on decentralizing privacy infrastructure (e.g., decentralized proof generation) allows for modular, secure applications that uphold data confidentiality without compromising performance.    What makes your project unique?  Privacy-first Approach: Horizen integrates a diverse stack of privacy-enhancing technologies (PETs) — including zero-knowledge proofs (ZKPs), trusted execution environments (TEEs), attribute-based encryption (ABE), multi-party computation (MPC), and fully homomorphic encryption (FHE) — to deliver scalable, flexible, and future-ready privacy solutions across its platform.  First Privacy Appchain on Base: As an L3 on Base, Horizen benefits from Ethereum’s security and Base’s scalability, while enabling a privacy layer for any app on the network. This unlocks new possibilities for private identity, DeFi, onchain gaming, and compliant confidential transactions.  Zero-Knowledge, Without the Trade-Offs: Horizen 2.0 scales ZK privacy and verification by integrating with leading zk infrastructure providers such as Fermah, zkVerify, and Singularity, optimizing proof generation for performance, cost-efficiency, and developer usability.  Token Utility Expansion: ZEN’s updated tokenomics allocates 5 million unminted tokens toward strategic ecosystem growth. ZEN powers DAO governance, serves as a payment token in privacy apps, and supports a sustainability fund to accelerate privacy innovation.  Developer-Centric Design: With EVM compatibility, privacy-friendly tooling, and the ability to embed privacy directly into smart contracts, Horizen allows developers to build privacy-first apps without requiring deep cryptographic expertise.  DAO-Led Governance: Governed by the Horizen DAO and shaped through community proposals (ZENIPs), Horizen is evolving as a fully decentralized protocol with transparent development and decision-making.    What can your coin/token be used for?  Horizen 2.0 delivers performance, privacy, and scalability for developers building privacy-enabled and compliance-friendly applications, with significantly reduced cost and latency.  At the core of the ecosystem is ZEN, the native utility token used for governance, accessing privacy services, and fueling zkApp interactions. With its migration to Base, ZEN becomes an ERC-20 token, improving liquidity, interoperability, and composability across the broader Ethereum ecosystem.

ZenCash

ZEN is trending as the community anticipates it will follow the price action of ZEC, with some eyeing a potential move to $25. Chatter revolves around ZEN's potential to breakout and longer term, a Grayscale trust filing and migration to Base are adding to the bullish sentiment.

Century Aluminum Co. is a producer of aluminum and operates aluminum reduction facilities, or smelters, in the United States and Iceland. Its products include standard ingots, T-ingot, extrusion billet, horizontal direct chill ingot, molten, slab, and sow. The company was founded in 1995 and is headquartered in Chicago, IL.

Century Aluminum Co.

Century Aluminum is trending due to a mix of factors, including a recent earnings miss despite higher sales, and Glencore's plan to sell a significant stake in the company. The community is actively discussing technical indicators, potential trading strategies around the 50-day moving average, and the implications of the earnings miss on the stock's potential rally, in addition to a new power deal with Santee Cooper.

Cummins, Inc. engages in the design, manufacture, and distribution of diesel, natural gas, electric and hybrid powertrains and powertrain-related components including filtration, aftertreatment, turbochargers, fuel systems, valvetrain technologies, controls systems, air handling systems, automated transmissions, axles, drivelines, brakes, suspension systems, electric power generation systems, batteries, electrified power systems, hydrogen production technologies, and fuel cell products. It operates through the following segments: Engine, Distribution, Components, Power Systems, and Accelera. The Engine segment manufactures and markets diesel and natural gas-powered engines under the Cummins brand name, for the heavy- and medium-duty truck, bus, recreational vehicle, light-duty automotive, construction, mining, marine, rail, oil and gas, defense, and agricultural markets. The Distribution segment includes power generation systems, high-horsepower engines, heavy-duty and medium-duty engines designed for on- and off-highway use, application engineering services, custom-designed assemblies, retail and wholesale aftermarket parts, and in-shop and field-based repair service. The Components segment supplies products including axles, drivelines, brakes and suspension systems for commercial diesel and natural gas applications, aftertreatment systems, turbochargers, fuel systems, valvetrain technologies, filtration products, automated transmissions, and electronics. The Power Systems segment engages in power generation, industrial, and generator technologies. The Accelera segment designs, manufactures, sells, and supports hydrogen production technologies, as well as electrified power systems, including battery, fuel cell, and electric powertrain technologies. The company was founded by Clessie Lyle Cummins and William Glanton Irwin on February 3, 1919 and is headquartered in Columbus, IN.

Cummins Inc.

Cummins is trending following an analyst target price increase from Barclays and Citi, with community members discussing the potential impact of increased data center buildouts on Cummins' power generation business and it's recent work in hydrogen. Positive ratings are tempered by an RSI approaching overbought and anticipation for earnings and forward guidance. Some traders are eyeing potential breakout gains, while others are considering pullback entry points.

The Children's Place, Inc. engages in the provision of apparel, footwear, accessories, and other items for children. The firm also designs contracts to manufacture and sell fashionable and value-priced merchandise under the brand names of The Children’s Place, Baby Place, and Gymboree. It operates through The Children’s Place U.S. and The Children’s Place International segments. The Children’s Place U.S. segment refers to the company’s U.S. and Puerto Rico-based stores and revenue from its U.S. based wholesale business. The Children’s Place International segment is involved in the Canadian-based stores, revenue from the company’s Canadian-based wholesale business, as well as revenue from international franchisees. The company was founded by David Pulver and Clinton A. Clark in 1969 and is headquartered in Secaucus, NJ.

Childrens Place Inc

PLCE is trending as investors discuss a potential short squeeze, with high short interest and a low float being key factors. The community is analyzing technical indicators and anticipating a significant price movement, particularly as the company shows signs of a turnaround and potential profitability. Some traders are also noting the impact of potential interest rate cuts and upcoming presentations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding

Groupon, BriaCell Therapeutics, and InnovAge shine as Zacks' top November picks for powerful earnings acceleration potential.

Top 3 Earnings Acceleration Buys for November 

Groupon, BriaCell Therapeutics and InnovAge stand out with accelerating earnings momentum as November's market optimism approaches. 

All You Need to Know About BRIACELL THERAP (BCTX) Rating Upgrade to Buy

BRIACELL THERAP (BCTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Shares of BriaCell Therapeutics Corp (BCTX) fell over 8% in Thursday's after-hours trading as the Canadian biotech firm priced a public offering of about $13.8 million.&nbsp;Retail investors, however, were focused on positive catalysts from earlier in the day.The West Vancouver, Canada-based company said it is issuing over 3 million shares at $4.50 apiece, more than 25% lower from the last closing price.The offer includes nearly 400,000 units sold through the full exercise of the underwriter's option.Each unit has one common share (or a pre-funded warrant) and one tradeable warrant.&nbsp;BriaCell expects to close the offering on April 28, pending customary closing conditions, and will use the proceeds for working capital, corporate purposes, and advancing its immunotherapy programs.Earlier on Thursday, BriaCell said that a patient in its Phase 1/2a Bria-OTS trial continues to show a complete resolution of lung metastasis, first reported in February 2025, now confirmed at the four-month mark. The news sent the stock up more than 11% in the regular session.The 78-year-old woman with metastatic breast cancer had previously&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bctx-stock-climbs-after-bria-ots-resolves-cancer-metastasis/chPYRuVRAQ">failed</a> several lines of therapy and received the lowest dose level in the study.Upon enrollment in November 2024, the patient had widespread disease, including lung, lymph node, and bone metastases.&nbsp;After receiving Bria-OTS injections every two weeks for six weeks, then every three weeks, her lung metastasis fully resolved, and stable disease has been maintained elsewhere in the body.On Stocktwits, the clinical news took precedence as sentiment for BriaCell turned even more 'extremely bullish' late Thursday amid a 1,266% jump in 24-hour message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/BCTX_sentiment_and_message_volume_as_of_April_24_png_c4da18642c.webp" alt="BCTX sentiment and message volume as of April 24.png" width="1318" height="316"><figcaption>BCTX sentiment and message volume as of April 24. | source: Stocktwits</figcaption></figure>"This is THE most undervalued biotech on NASDAQ, and that will be proven in coming months," posted one user.<stembedurl>https://stocktwits.com/Fvalstounge/message/612629738</stembedurl>"This company should be worth several billion dollars... WOW," wrote another.<stembedurl>https://stocktwits.com/Hannibal_Smith/message/61253769</stembedurl>BriaCell stock, however, has lost over 82% in the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail's Busy Cheering Clinical Milestone

Earlier on Thursday, BriaCell said that a patient in its Phase 1/2a Bria-OTS trial continues to show a complete resolution of lung metastasis.

Equity

Earlier on Thursday, BriaCell said that a patient in its Phase 1/2a Bria-OTS trial continues to show a complete resolution of lung metastasis.


Nasdaq-listed shares of BriaCell Therapeutics Corp. (BCTX) traded nearly 12% higher on Wednesday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=6008109823653589&amp;symbol=BCTX">announced</a> positive survival data in its Phase 2 study of Bria-IMT plus check point inhibitors (CPI).The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients.The survival data of patients enrolled in the study with hormone receptor-positive (HR+) metastatic breast cancer exceeds those of patients treated with the prescription medicine Trodelvy, the company said.HR+ metastatic breast cancer patients treated with Bria-IMT plus check point inhibitors had a median overall survival of 17.3 months, exceeding the 14.4 months with Trodelvy in similar heavily pre-treated patients.In patients with triple negative breast cancer, the survival data was similar to patients on Trodelvy but still 70% higher than those of chemotherapy, the company said.CEO William V Williams expressed optimism about the survival benefit data.“Bria-IMT appears to be very well-tolerated,” he said, adding that the company looks forward to confirming the data in its Phase 3 study.Patients with HR+ and TNBC metastatic breast cancer have an overall survival of only a few months and limited therapeutic options.Earlier this month, BriaCell’s majority-owned subsidiary BriaPro Therapeutics Corp announced that it is developing antibodies to B7-H3, a key player in cancer progression, using molecular modeling techniques.On Stocktwits, retail sentiment around BriaCell Therapeutics rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’.<figure class="image"><img style="aspect-ratio:1298/304;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_16_at_12_16_46_PM_png_18e64dcd73.webp" alt="BCTX's Sentiment Meter and Message Volume as of 12:15 p.m. ET on April 16, 2025 | Source: Stocktwits" width="1298" height="304"><figcaption>BCTX's Sentiment Meter and Message Volume as of 12:15 p.m. ET on April 16, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/BCTX">BCTX stock</a> is down by about 52% year-to-date and by about 88% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/icad-stock-soars-merger-announcement-with-radnet/chQPV8HRbOq">iCAD Stock Rockets On Merger Announcement With RadNet: Retail’s Elated</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

BriaCell Stock Rises On Positive Survival Data From Study In Cancer Patients: Retail Gets More Bullish

HR+ metastatic breast cancer patients treated with Bria-IMT plus check point inhibitors had a median overall survival of 17.3 months, exceeding the 14.4 months with Trodelvy in similar heavily pre-treated patients, the company said. 

Shares of BriaCell Therapeutics Corp. rose nearly 2% on Monday afternoon, reversing earlier losses as traders reacted to promising clinical data. Trading volume surged to over 90 times the daily average of about 146,000 shares.BriaCell announced what it called an “unprecedented clinical response,” including the complete resolution of a lung metastasis in a patient with metastatic breast cancer.&nbsp;The patient, a 78-year-old woman who had failed multiple prior treatments, was the first to receive Bria-OTS, a personalized off-the-shelf immunotherapy currently being tested in a Phase 1/2a dose escalation study.At the time of enrollment on Nov. 21, 2024, she had extensive metastases, including multiple bone, lymph node, and lung lesions, according to the company.&nbsp;After receiving four Bria-OTS injections over two weeks, her lung metastasis completely disappeared, while the disease remained stable elsewhere, BriaCell said.Bria-OTS is a next-generation, personalized advancement of BriaCell’s lead candidate, Bria-IMT, which is currently in a pivotal Phase 3 study for metastatic breast cancer.By Monday afternoon, BriaCell was among the top trending tickers on Stocktwits, with the retail messages largely optimistic.“The data on this patient is a true game changer,” wrote one trader, alleging that earlier weakness in the stock was due to short-seller manipulation.<stembedurl>https://stocktwits.com/JJBurch/message/602660557</stembedurl>Traders also noted that H.C. Wainwright more than doubled its price target on BriaCell to $32, implying a nearly 700% upside from current levels.<stembedurl>https://stocktwits.com/Jaymes11/message/602663519</stembedurl>Despite Monday’s gains, BriaCell shares remain down over 90% in the past year. Message volume on Stocktwits has more than tripled in that period, reflecting growing retail interest.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

BriaCell Stock Climbs After ‘Unprecedented’ Immunotherapy Response In Breast Cancer Patient, Retail Exudes Optimism

Bria-OTS is a next-generation, personalized advancement of BriaCell’s lead candidate, Bria-IMT, which is currently in a pivotal Phase 3 study for metastatic breast cancer.

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters.&nbsp;Our focus is on quality, liquid, growth-oriented, and under-followed companies in sectors actively drawing in capital such as AI, blockchain, biotech and consumer.&nbsp;This real-time news surveillance and targeting combined with our proprietary 5-point analysis, aids in uncovering stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.&nbsp;Here’s what we’re keeping our eyes on:<h3>1. Purple Biotech (NASDAQ: PPBT)</h3>Background: Purple Biotech is a clinical-stage oncology company that aims to redefine cancer treatment through its innovative approaches targeting tumor immune evasion and drug resistance. Its lead product, CM24, is a first-in-class anti-CEACAM1 antibody being developed to treat pancreatic and other aggressive cancers. The oncology space, worth billions, continues to see intense investor interest, especially as companies explore biomarker-driven therapies.The News: Purple Biotech unveiled final Phase 2 results showing CM24 combined with nivolumab and chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) in pancreatic cancer patients with specific biomarkers. The data revealed a 79% reduction in death risk and a 5.1-month OS improvement, particularly in biomarker-enriched patient groups.What It Means: These results not only validate CM24’s potential but also position Purple Biotech to expand its pipeline into broader cancer applications. With a planned Phase 2b trial targeting high-CEACAM1 patients, the company is tapping into precision oncology—a sector that continues to draw investor enthusiasm due to its game-changing potential.Stock Reaction: PPBT skyrocketed 151%, reflecting the market’s recognition of this major milestone in the fight against pancreatic cancer.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_23_40_AM_19763a2e26.png" alt="Screenshot 2024-12-05 at 2.23.40 AM.png">&nbsp;<hr>&nbsp;<h3>2. Stereotaxis (NYSE: STXS)</h3>Background: Stereotaxis is at the forefront of surgical robotics, specializing in robotic magnetic navigation (RMN) systems for minimally invasive endovascular interventions. Its GenesisX system aims to improve precision, safety, and efficiency in procedures, a critical innovation as the global market for robotic-assisted surgeries is projected to grow at a double-digit CAGR over the next decade.The News: The GenesisX robotic system was showcased for the first time at the RSNA 2024 Annual Meeting, in collaboration with Neusoft Medical Systems. The partnership aligns GenesisX with advanced imaging technologies, offering enhanced capabilities for healthcare providers worldwide.What It Means: The exposure at RSNA, one of the largest radiology conferences globally, strengthens Stereotaxis' visibility and positions the GenesisX as a next-generation tool for minimally invasive surgeries. This partnership could unlock new revenue streams as the healthcare sector increasingly adopts robotic solutions.Stock Reaction: STXS edged up 4.18%, with investors optimistic about the long-term implications of the GenesisX system.Stocktwits.com Sentiment &amp; Popularity:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_25_09_AM_6fecf5b145.png" alt="Screenshot 2024-12-05 at 2.25.09 AM.png">&nbsp;<hr>&nbsp;<h3>3. Delcath Systems (NASDAQ: DCTH)</h3>Background: Delcath Systems focuses on innovative therapies for primary and metastatic liver cancers. Its flagship product, HEPZATO KIT™, offers a unique approach to delivering high-dose chemotherapy directly to the liver while minimizing systemic exposure. This precision is critical for targeting liver-dominant diseases—a market that represents tens of thousands of patients annually.The News: The FDA has cleared Delcath’s Phase 2 trial of HEPZATO in liver-dominant metastatic colorectal cancer. The study will compare HEPZATO plus standard chemotherapy with chemotherapy alone, aiming to validate its safety and efficacy in this high-need population.What It Means: HEPZATO has already shown promise in metastatic uveal melanoma, and this expansion could significantly broaden its market reach. The ability to address liver-dominant cancers positions Delcath as a potential leader in a niche but high-value market.Stock Reaction: DCTH rose 6.4% on the day, continuing its strong performance following a 203% year-to-date rally.&nbsp;&nbsp;<hr>&nbsp;<h3>4. BrainStorm Cell Therapeutics (NASDAQ: BCLI)</h3>Background: BrainStorm is a pioneering biotech company developing autologous adult stem cell therapies for neurodegenerative diseases like ALS and progressive MS. Its lead candidate, NurOwn®, is designed to deliver neurotrophic factors directly to damaged neurons, potentially altering the course of these debilitating diseases. With few effective therapies for ALS, the market is ripe for disruptive innovation.The News: BrainStorm announced a December 11 webinar featuring updates on its Phase 3b trial of NurOwn, aimed at refining the therapy’s efficacy for FDA approval. This comes as the company prepares for a pivotal registrational trial.What It Means: If successful, NurOwn could be the first significant breakthrough for ALS in years, addressing an unmet medical need in a multibillion-dollar market. The company’s focus on early-stage ALS patients may improve trial outcomes and strengthen its case for regulatory approval.Stock Reaction: BCLI dipped 2.66%, reflecting cautious investor sentiment as the market awaits trial data.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_26_15_AM_28681ca8de.png" alt="Screenshot 2024-12-05 at 2.26.15 AM.png">&nbsp;<hr>&nbsp;<h3>5. DMG Blockchain Solutions (OTCQB: DMGGF)</h3>Background: DMG Blockchain integrates Bitcoin mining with sustainability and AI-driven data centers. Its Terra Pool initiative is designed to create a carbon-neutral Bitcoin mining ecosystem, catering to ESG-conscious investors and industries. With institutional adoption of Bitcoin accelerating, DMG’s dual focus on growth and environmental responsibility makes it a standout.The News: DMG reported November mining results of 32 BTC, an increased hashrate of 1.66 EH/s, and significant insider purchases by its CEO and COO. The company also secured $17.3 million to fund growth initiatives, including AI and blockchain infrastructure.What It Means: The raised capital and insider purchases signal confidence in DMG’s ability to scale operations and align with Bitcoin’s anticipated market growth. The focus on sustainability could attract institutional players prioritizing ESG compliance.Stock Reaction: DMGI remained stable dipping just slightly, with the market digesting the long-term growth potential from recent investments.&nbsp;<hr>&nbsp;<h3>6. BriaCell Therapeutics (NASDAQ: BCTX)</h3>Background: BriaCell specializes in novel immunotherapies targeting advanced breast cancer. Its lead therapy, Bria-IMT™, is designed to boost the immune system's response against tumors. With metastatic breast cancer affecting over 2 million women globally, there’s an urgent need for effective treatments.The News: BriaCell’s pivotal Phase 3 study of Bria-IMT received a positive safety review from the DSMB, allowing the trial to proceed without changes. The trial is being conducted under the FDA’s Fast Track Designation.What It Means: The DSMB’s approval reinforces Bria-IMT’s safety and paves the way for the company to potentially deliver a game-changing therapy for metastatic breast cancer patients. The Fast Track Designation further emphasizes its potential impact.Stock Reaction: BCTX shares soared 13%, reflecting growing investor confidence in the company’s clinical progress.Rumours from Twitter:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_27_31_AM_e685b0a306.png" alt="Screenshot 2024-12-05 at 2.27.31 AM.png">&nbsp;&nbsp;<h3>7. Laser Photonics Corporation (NASDAQ: LASE)</h3>Background: Laser Photonics Corporation specializes in industrial laser systems, providing innovative solutions for cleaning, material processing, and now pharmaceuticals. With its recent acquisition of Control Micro Systems, Inc., the company is expanding into new sectors, including the fast-growing pharmaceutical and semiconductor industries. The industrial laser market, driven by advances in automation and precision engineering, is projected to exceed $10 billion by 2030, making it a hotbed for innovation.The News: Laser Photonics announced the successful installation of a state-of-the-art pill drilling system at a customer’s facility. The system, a Class I automated CO2 laser with advanced fume extraction and machine vision inspection, is designed to streamline pill production processes. This system also doubles as an anti-counterfeiting solution, addressing critical challenges in the pharmaceutical supply chain.What It Means: This installation signifies Laser Photonics’ pivot into high-demand verticals like pharmaceuticals. By integrating advanced laser technology with automated inspection, the company is positioning itself as a key supplier in a market prioritizing efficiency, precision, and security.Stock Reaction: LASE shares declined 6.40%, reflecting broader market volatility rather than company-specific concerns. Investors appear cautiously optimistic about the company's potential in its newly targeted markets.&nbsp;Also Read:<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/why-this-small-biotech-stock-could-be-primed-for-a-breakout/">&nbsp;Why This Small Biotech Stock Could Be Primed for a Breakout</a>Be the First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like&nbsp;AST SpaceMobile (NASDAQ: ASTS), which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a long or short position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Yesterday’s Hottest News That Could Move the Needle Today

Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend PR Newswire VANCOUVER, BC, Dec. 2, 2024 USA...

Why Is Breast Cancer-Focused BriaCell Therapeutics Stock Trading Over 100% On Wednesday

BriaCell Therapeutics stock rises on positive Phase 2 trial results showing improved survival in late-stage metastatic breast cancer patients treated with Bria-IMT and an immune checkpoint...

Short Interest in BriaCell Therapeutics Corp. (NASDAQ:BCTX) Drops By 7.9%

BriaCell Therapeutics Corp. (NASDAQ:BCTX - Get Free Report) was the recipient of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling...

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp - Ordinary Shares - New

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

BCTX
BriaCell Therapeutics Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BCTX News

BCTXBriaCell Therapeutics Corp